Clinical trial · Interventional
Optimization of the Core Number and Location for Targeted Prostate Biopsy
An Exploratory Study of Optimizing the Core Number and Location for MRI/Ultrasound Fusion Targeted Prostate Biopsy
NCT04983706CI-TRIAL-00052999unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate the effect of core number and location optimization for targeted prostate biopsy on pathological accuracy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI/Ultrasound Fusion Saturation Biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MRI/Ultrasound Fusion Saturation Biopsy
- interventionNames
- Procedure: MRI/Ultrasound Fusion Saturation Biopsy
Primary outcomes (1)
- measure
- The significant prostate cancer detection rate with different combinations of core number and location in the targeted saturated biopsy area
- timeFrame
- When histology results available, at an expected average of 3 days post-biopsy
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Men more than 18 years old with clinical suspicion of prostate cancer; 2. Serum PSA ≤ 20 ng/ml within the previous 3 months; 3. No evidence of PSA increase by noncancerous factors, such as catheterization, bladder stones, or urinary tract infection including bacterial prostatitis; 4. mpMRI PI-RADS V2.1 score ≥4, diameter of ≤2.5 cm； 5. Able to provide written informed consent. Exclusion Criteria: 1. Prior prostate biopsy or prostate surgery; 2. Prior treatment for prostate cancer; 3. Contraindication to MRI (e.g. claustrophobia, pacemaker); 4. Contraindication to prostate biopsy; 5. Men in whom artifact would reduce the quality of the MRI.
References
Publications (0)
Data not yet available
No reference posted for this study.